The consensus price target for Akeso has increased to HK$169.47, primarily reflecting a higher expected future P/E despite a modest decline in net profit margin.
What's in the News
- Akeso is advancing multiple late-stage global trials for its bispecific antibodies, notably cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), across several cancer types including HCC, NSCLC, gastric, pancreatic, biliary tract, and colorectal cancers, with several studies meeting or surpassing primary endpoints and demonstrating significant clinical benefits over existing therapies.
- The company is expanding into new therapeutic areas beyond oncology, reporting positive Phase 3 results for gumokimab in ankylosing spondylitis and manfidokimab in atopic dermatitis, as well as advancing pipeline candidates for other autoimmune and inflammatory diseases.
- Multiple registration and data milestones have been achieved recently, including sNDA acceptance for ivonescimab in new NSCLC indications, positive long-term OS and PFS outcomes for ivonescimab in Phase III lung cancer trials, and first-in-human dosing for innovative bispecific ADCs targeting multiple tumor antigens.
- Akeso completed a follow-on equity offering, raising approximately HKD 3.52 billion through a direct listing of ordinary shares, supporting continued R&D and global expansion.
- The company maintains a robust pipeline with over 50 assets, 24 in clinical stages (15 bispecific/multispecific antibodies and ADCs), 7 new drugs already commercially available, and further global late-stage trials in planning or underway for additional oncology and immunology indications.
Valuation Changes
Summary of Valuation Changes for Akeso
- The Consensus Analyst Price Target has risen from HK$158.71 to HK$169.47.
- The Future P/E for Akeso has significantly risen from 40.38x to 44.60x.
- The Net Profit Margin for Akeso has fallen slightly from 42.34% to 40.81%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.